Latanoprost-Optic eye drops 0.005%, 5ml

1 drop into the affected eye 1 time / day, preferably in the evening.

Eye drops are transparent, colorless.

1 ml

latanoprost 0.05 mg

Excipients: benzalkonium chloride in terms of anhydrous substance - 0.2 mg, sodium chloride - 4.1 mg, sodium dihydrogen phosphate monohydrate - 4.6 mg, sodium hydrogen phosphate anhydrous - 4.74 mg, purified water - up to 1 ml.

Hypersensitivity to latanoprost.

pharmachologic effect

Antiglaucoma remedy. An analogue of prostaglandin F2 ?, is a selective FP receptor antagonist. Reduces intraocular pressure by increasing the uveoscleral outflow of aqueous humor. Does not significantly affect the production of aqueous humor and the blood-ophthalmic barrier. It is isopropyl ether - an inactive precursor, the hydrolysis of which leads to the formation of the pharmacologically active acid latanoprost.

Side effect

Possibly: sensation of a foreign body in the eye, mild or moderate hyperemia, punctate epithelial erosion. In isolated cases: macular edema in patients with aphakia or pseudophakia with a lens in the anterior chamber of the eye.

Application during pregnancy and lactation

Application during pregnancy and lactation is possible in cases where the expected benefit of treatment for the mother outweighs the potential risk to the fetus or child.

Application in children

The safety of use in children has not been established, therefore, use in pediatrics is not recommended.

special instructions

Use with caution in secondary (due to inflammatory disease or trauma), congenital glaucoma, in open-angle glaucoma in patients with pseudophakia, as well as in pigmented glaucoma; angle-closure glaucoma (including with an acute attack). Latanoprost can cause a gradual change in eye color by increasing the brown pigment in the iris. This is observed mainly in patients with mixed iris coloration and is not accompanied by any clinical symptoms or pathological changes, but may be irreversible. It should be borne in mind that latanoprost and its metabolites may be excreted in breast milk. The safety of use in children has not been established, therefore, use in pediatrics is not recommended. Should be used with caution in patients engaged in potentially hazardous activities,requiring a high speed of psychomotor reactions.

Drug interactions

With simultaneous use with timolol, adrenergic agonists, acetazolamide, pilocarpine, an additive effect on intraocular pressure is observed.